Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Barclays PLC

Barclays PLC boosted its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 310.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,301 shares of the company's stock after buying an additional 39,567 shares during the period. Barclays PLC owned approximately 0.19% of Castle Biosciences worth $1,491,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in CSTL. Point72 Asset Management L.P. increased its holdings in shares of Castle Biosciences by 828.3% during the third quarter. Point72 Asset Management L.P. now owns 499,192 shares of the company's stock valued at $14,237,000 after acquiring an additional 445,415 shares in the last quarter. Marshall Wace LLP increased its position in shares of Castle Biosciences by 116.5% during the second quarter. Marshall Wace LLP now owns 212,036 shares of the company's stock worth $4,616,000 after acquiring an additional 114,104 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Castle Biosciences by 147.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company's stock worth $4,719,000 after acquiring an additional 98,571 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Castle Biosciences by 47.3% during the 2nd quarter. Renaissance Technologies LLC now owns 301,500 shares of the company's stock worth $6,564,000 after purchasing an additional 96,800 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Castle Biosciences by 9.8% in the third quarter. State Street Corp now owns 680,001 shares of the company's stock worth $19,394,000 after purchasing an additional 60,924 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Castle Biosciences

In related news, insider Tobin W. Juvenal sold 3,507 shares of the business's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the sale, the insider now directly owns 54,178 shares in the company, valued at approximately $1,926,569.68. The trade was a 6.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Derek J. Maetzold sold 2,715 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $29.62, for a total value of $80,418.30. Following the completion of the transaction, the insider now owns 82,047 shares in the company, valued at $2,430,232.14. This represents a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,320 shares of company stock worth $1,036,119. 7.20% of the stock is currently owned by insiders.

Castle Biosciences Stock Down 0.8 %

CSTL opened at $30.00 on Monday. The stock has a market capitalization of $840.21 million, a price-to-earnings ratio of 150.01 and a beta of 0.92. The firm has a 50 day moving average price of $29.81 and a 200-day moving average price of $27.96. Castle Biosciences, Inc. has a twelve month low of $16.97 and a twelve month high of $35.84. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.14. The company had revenue of $85.78 million during the quarter, compared to the consensus estimate of $78.55 million. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. During the same period in the previous year, the company posted ($0.26) EPS. Equities research analysts forecast that Castle Biosciences, Inc. will post 0.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Scotiabank increased their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a "sector outperform" rating in a research report on Wednesday, November 6th. BTIG Research raised their price objective on shares of Castle Biosciences from $35.00 to $40.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Canaccord Genuity Group increased their target price on shares of Castle Biosciences from $35.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, October 29th. Lake Street Capital lifted their target price on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Finally, Robert W. Baird raised their price objective on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $40.29.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.